Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01473
|
|||||
| Drug Name |
Zoledronic acid
|
|||||
| Synonyms |
Aclasta; Reclast; ZOL; Zometa; Novartis brand of zoledronic acid; Zoledronic acid; Zometa Concentrate; Bisphosphonate 3; CGP 42446; CGP 42446A; Aclasta (TN); CGP 42'446; CGP-42446; KS-1132; Reclast (TN); Zoledronic acid (INN); Zoledronic acid [USAN:INN]; Zomera (TN); Zometa (Novartis); Zometa (TN); CGP-42'446; Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid; [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid); (1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid; (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid; (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid; (1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate; 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid; 2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Paget's disease [ICD11: FB85] | Approved | [1] | |||
| Therapeutic Class |
Bone Density Conservation Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C5H10N2O7P2
|
|||||
| Canonical SMILES |
C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O
|
|||||
| InChI |
InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)
|
|||||
| InChIKey |
XRASPMIURGNCCH-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 118072-93-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 272.09 | Topological Polar Surface Area | 153 | ||
| Heavy Atom Count | 16 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 5 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
-4.3
|
|||||
| PubChem CID | ||||||
| PubChem SID |
536160
, 6436371
, 7891233
, 7980916
, 8192311
, 10318362
, 10318375
, 10318390
, 10318944
, 11528905
, 14824151
, 25819963
, 29215499
, 29215500
, 43125267
, 46507310
, 46513035
, 50473172
, 53788750
, 53801236
, 56311814
, 56436259
, 56479320
, 57317038
, 81092860
, 85174457
, 87457600
, 89736141
, 92308965
, 92712542
, 93166450
, 93167152
, 96025372
, 99343600
, 99343604
, 99437087
, 99455519
, 103240897
, 104342928
, 109692939
, 117626547
, 118048654
, 124757161
, 125163965
, 125338822
, 126592903
, 126625470
, 126656631
, 126667014
, 127324075
|
|||||
| ChEBI ID |
ChEBI:46557
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MRP1 | Transporter Info | Multidrug resistance-associated protein 1 | Substrate | [2] | |
| References | ||||||
| 1 | zoledronic acid was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Zoledronic acid is synergic with vinblastine to induce apoptosis in a multidrug resistance protein-1 dependent way: an in vitro study. Cell Biol Int. 2006 Mar;30(3):278-82. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.